Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | CITADEL-101 study- Parsaclisib in R/R B-cell malignancies

Tycel Phillips • 3 Jun 2019
ASCO 2019
Lymphoma Non-Hodgkin Lymphoma Parsaclisib

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses the CITADEL-101 trial (NCT02018861) investigating the maximum tolerated dose or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with itacitinib, This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Tycel Phillips

The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more 15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Michael Wang et al. • 27 Sep 2025
The development of predictive biomarkers for bispecifics, CAR-T, or ADCs in lymphoma 2:36
The development of predictive biomarkers for bispecifics, CAR-T, or ADCs in lymphoma
Tycel Phillips • 5 Sep 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals